date:May 21, 2012
DSM board member Stephan Tanda told us the drug route was largely unexplored as ONC does little business in that space, but events were conspiring in its favour as GlaxoSmithKlines blockbuster lipid regulator, Lovaza, is set to go off patent later this year.
So there is the option to participate in the generic drug space, but this market is yet to be developed, so it remains an option, Tanda said, noting that did not detract from DSMs ambition to, accelerate penetration into European and emerg